CYTOMX THERAPEUTICS INC (CTMX)

Company Profile

CytomX Therapeutics, Inc. is a clinical-stage, oncology-focused biopharmaceutical company, which engages in the development of conditionally activated, biologics localized to the tumor microenvironment. The company is headquartered in South San Francisco, California and currently employs 116 full-time employees. The company went IPO on 2015-10-08. The firm is developing a class of investigational conditionally activated therapeutics, based on its Probody technology platform, for the treatment of cancer. Its Probody technology platform is designed to enable conditional activation of antibody-based drugs in the tumor microenvironment while minimizing drug activity in healthy tissues and in circulation. Its pipeline comprises therapeutic candidates across multiple treatment modalities including antibody-drug conjugates, T-cell engaging bispecific antibodies (TCBs), and immune modulators such as cytokines and checkpoint inhibitors (CPIs). Its clinical pipeline also includes cancer immunotherapeutic candidates. Its product candidates include CX-2029, CX-904, CX-2051, CX-801 and BMS-986288. Its CX-2029 is a Probody ADC targeting CD71 for the treatment of patients with squamous non-small cell lung carcinoma (sqNSCLC) and esophageal cancers.

Company Info

CYTOMX THERAPEUTICS INC

151 Oyster Point Blvd., Suite 400

South San Francisco CALIFORNIA 94080

P: 16505153185

CEO: Sean A. McCarthy

Employees: 116

Website: https://cytomx.com/